Leidos Awarded Contract by Naval Medical Logistics Command

Company to Provide Services in Support of HIV/AIDS Prevention Programs

News provided by

Sep 22, 2014, 04:05 ET

RESTON, Va., Sept. 22, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health, and engineering solutions company, was awarded a prime contract by the Naval Medical Logistics Command (NMLC) to provide services in support of the Naval Health Research Center's (NHRC), Department of Defense (DoD), HIV/AIDS Prevention Program (DHAPP). The single-award cost-plus fixed-fee contract has a one-year base period of performance, four one-year options and a total contract value of approximately $14 million if the options are exercised. Work will be performed in San Diego, Calif.

NHRC, as part of the DoD's program to reduce HIV/AIDS in Allied Nations' Uniformed Services, identifies and supports organizations with novel approaches to developing laboratory and clinical HIV/AIDS education and prevention programs. DHAPP provides day-to-day direction of the DoD effort.

Under the contract, Leidos will provide services in support of HIV/AIDS prevention programs, including, assisting in the establishment of HIV/AIDS-specific policies for foreign military personnel, assisting in the adaption of prevention programs, training military personnel in selected foreign militaries to implement, maintain and evaluate HIV/AIDS prevention, treatment and clinical management programs, and assisting in the integration of U.S. Government programs and those managed by allies and the United Nations.

"Despite the advancements in treatments over the last several years, HIV/AIDS is still a public health crisis in many regions in the world," said Steve Comber, Group President of Leidos Health. "We are proud to support NHRC, the Department of Defense and other Allied Nations in their efforts to develop education and prevention programs to mitigate the HIV epidemic and prevent the AIDS virus from spreading further."

About Leidos Health
As a leader for more than 25 years in the healthcare industry, Leidos Health fuses some of the world's most advanced technologies with the brightest minds in science, research and consulting. Today, Leidos Health is focused on developing next-generation solutions in areas such as biomedical research, public health and health analytics to turn data into actionable information for clinicians and their patients. From leading groundbreaking medical research to fighting diseases such as cancer, AIDS and malaria, to implementing and optimizing electronic health records that enhance the research process and improve critical efficiencies – Leidos Health's passion to improve patient care and reduce costs is helping to transform healthcare. For more information, visit www.Leidos.com/health.

About Leidos
Leidos is a FORTUNE 500^® science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 22,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $5.77 billion for its fiscal year ended January 31, 2014 after giving effect to the spin-off of the company's technical services and information technology business. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 31, 2014, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.